Optimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: the key issue for development of anti-tumor vaccines
Tóm tắt
Từ khóa
Tài liệu tham khảo
Vesely M, Kershaw M, Schreiber R, Smyth M: Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011, 29: 235-271. 10.1146/annurev-immunol-031210-101324.
Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004, 10: 909-915. 10.1038/nm1100.
Jochems C, Schlom J: Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity. Exp Biol Med. 2011, 236: 567-579. 10.1258/ebm.2011.011007.
de Visser KE, Eichten A, Coussens LM: Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006, 6: 24-37. 10.1038/nrc1782.
Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, Rimoldi M, Biswas SK, Allavena P, Mantovani A: Macrophage polarization in tumour progression. Sem Cancer Biol. 2008, 18: 349-355. 10.1016/j.semcancer.2008.03.004.
Sakaguchi S, Sakaguchi N, Asano M, Itoh MMT: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995, 155: 1151-1164.
Nishikawa H, Sakaguchi S: Regulatory T cells in tumor immunity. Int J Cancer. 2010, 127: 759-767.
Mantovani A, Sica A: Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010, 22: 231-237. 10.1016/j.coi.2010.01.009.
Ruffell B, DeNardo DG, Affara NI, Coussens LM: Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev. 2010, 21: 3-10. 10.1016/j.cytogfr.2009.11.002.
Hui K, Grosveld F, Festenstein H: Rejection of transplantable AKR leukemia cells following DNA-mediated cell transformation. Nature. 1984, 311: 750-752. 10.1038/311750a0.
De Plaen E, Lurquin C, Lethe B, van der Bruggen P, Brichard V, Renauld JC, Coulie P, Van Pel A, Boon T: Identification of genes coding for tumor antigens recognized by cytolytic T lymphocytes. Methods. 1997, 12: 125-142. 10.1006/meth.1997.0462.
Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME: Adoptive cell therapy: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008, 8: 299-308. 10.1038/nrc2355.
Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S: Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol. 1999, 154: 745-754. 10.1016/S0002-9440(10)65321-7.
Garcia-Lora A, Algarra I, Garrido F: MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol. 2003, 195: 346-355. 10.1002/jcp.10290.
Garrido F, Algarra I, García-Lora AM: The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible “hard” lesions. Cancer Immunol Immunother. 2010, 59: 1601-1606. 10.1007/s00262-010-0893-2.
Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ: Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med. 1998, 187: 693-702. 10.1084/jem.187.5.693.
Pardoll DM, Topalian SL: The role of CD4+ T cell responses in anti-tumor immunity. Curr Opin Immunol. 1998, 10: 588-594. 10.1016/S0952-7915(98)80228-8.
Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll DM, Levitsky H: The central role of CD4+ T cells in the antitumor immune response. J Exp Med. 1998, 188: 2357-2368. 10.1084/jem.188.12.2357.
Germain RN, Margulies DH: The biochemistry and cellular biology of antigen processing and presentation. Annu Rev Immunol. 1993, 11: 403-450. 10.1146/annurev.iy.11.040193.002155.
Mitchison NA: Induction of immunological paralysis in two zones of dosage. Proc R Soc Lond. 1964, 161 (983): 275-292. 10.1098/rspb.1964.0093.
Makela O, Mitchison NA: The effect of antigen dosage on the response of adoptively transferred cells. Immunology. 1965, 8: 549-556.
Zinkernagel RM, Ehl S, Aichele P, Oehen S, Kundig TM, Hengartner H: Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev. 1997, 156: 199-209. 10.1111/j.1600-065X.1997.tb00969.x.
Dranoff G: Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 2004, 4: 11-22. 10.1038/nrc1252.
Accolla RS, Jotterand-Bellomo M, Scarpellino L, Maffei A, Carra G, Guardiola J: Air-1, a newly found locus on mouse chromosome 16 encoding a trans-acting activator factor for MHC class II gene expression. J Exp Med. 1986, 164: 369-374. 10.1084/jem.164.1.369.
Steimle V, Otten LA, Zufferey M, Mach B: Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or Bare Lymphocyte Syndrome). Cell. 1993, 75: 135-146.
Meazza R, Comes A, Orengo AM, Ferrini S, Accolla RS: Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells. Eur J Immunol. 2003, 33: 1183-1192. 10.1002/eji.200323712.
Harton JA, Ting JPY: Class II transactivator: mastering the art of major histocompatibility complex expression. Mol Cell Biol. 2000, 20: 6185-6194. 10.1128/MCB.20.17.6185-6194.2000.
Rudensky A, Preston-Hurlburt P, Hong SC, Barlow A, Janeway CAJ: Sequence analysis of peptides bound to MHC class II molecules. Nature. 1991, 353: 622-627. 10.1038/353622a0.
Schimd D, Pypaert M, Munz C: Antigen-loading compartments for major histocompatibility class II molecules continuously receive input from autophagosomes. Immunity. 2007, 26: 79-92. 10.1016/j.immuni.2006.10.018.
Chicz RM, Urban RG, Gorga JC, Vignali DA, Lane WS, Strominger JL: Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med. 1993, 178: 27-47. 10.1084/jem.178.1.27.
Jaraquemada D, Marti M, Long EO: An endogenous processing pathway in vaccinia virus-infected cells for presentation of cytosolic antigens to MHC class II-restricted T cells. J Exp Med. 1990, 172: 947-954. 10.1084/jem.172.3.947.
Mortara L, Castellani P, Meazza R, Tosi G, De Lerma Barbaro A, Procopio FA, Comes A, Zardi L, Ferrini S, Accolla RS: CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory. Clin Cancer Res. 2006, 12: 3435-3443. 10.1158/1078-0432.CCR-06-0165.
Frangione V, Mortara L, Castellani P, De Lerma Barbaro A, Accolla RS: CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of anti-tumor CD4+ T lymphocytes for immunotherapy. Int J Cancer. 2010, 127: 1614-1624. 10.1002/ijc.25183.
Mortara L, Frangione V, Castellani P, De Lerma Barbaro A, Accolla RS: Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions. Int Immunol. 2009, 21: 655-665. 10.1093/intimm/dxp034.
Sartoris S, Valle MT, De Lerma Barbaro A, Tosi G, Cestari T, D’Agostino AMMA, Manca F, Accolla RS: HLA class II expression in uninducible hepatocarcinoma cells after trasfection of the AIR-1 gene product CIITA. Acquisition of antigen processing and presentation capacity. J Immunol. 1998, 161: 814-820.
Armstrong T, Clements V, Ostrand-Rosenberg S: MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes. J Immunol. 1998, 160: 661-666.
Qi L, Rojas J, Ostrand-Rosenberg S: Tumor cells present MHC class II-restricted nuclear and mitochondrial antigens and are the predominant antigen presenting cells in vivo. J Immunol. 2000, 165: 5451-5461.
Dissanayake S, Tuera N, Ostrand-Rosenberg S: Presentation of endogenously synthesized MHC class II-restricted epitopes by MHC class II cancer vaccines is independent of transporter associated with Ag processing and the proteasome. J Immunol. 2005, 174: 1811-1819.
Bonehill A, Heirman C, Tuyaerts S, Michiels A, Zhang Y, van der Bruggen P, Thielemans K: Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an Invariant chain with genetic exchange of class II-associated Invariant Chain Peptide. Cancer Res. 2003, 63: 5587-5594.
Brulet J-M, Maudoux F, Thomas S, Thielemans K, Burny A, Leo O, Bex F, Hallez S: DNA vaccine encoding endosome-targeted human papillomavirus type 16 E7 protein generates CD4+ T celldependent protection. Eur J Immunol. 2007, 37: 376-384. 10.1002/eji.200636233.
Mittendorf EA, Holmes JP, Murray JL, von Hofe E, Peoples GE: CD4+ T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37). Expert Opin Biol Ther. 2009, 9: 71-78. 10.1517/14712590802614538.
Atanackovic D, Luetkens T, Kloth B, Fuchs G, Cao Y, Hildebrandt Y, Meyer S, Bartels K, Reinhard H, Lajmi N: Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia. Am J Hematol. 2011, 86: 918-922. 10.1002/ajh.22141.
Claus R, Almstedt M, Lubbert M: Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents. Semin Oncol. 2005, 32: 511-520. 10.1053/j.seminoncol.2005.07.024.
Borsi L, Balza E, Carnemolla B, Sassi F, Castellani P, Berndt A, Kosmehl H, Biro A, Siri A, Orecchia P: Selective targeted delivery of TNFalpha to tumor blood vessels. Blood. 2003, 102: 4384-4392. 10.1182/blood-2003-04-1039.
Balza E, Mortara L, Sassi F, Monteghirfo S, Carnemolla B, Castellani P, Neri D, Accolla RS, Zardi L, Borsi L: Targeted delivery of tumor necrosis factor-a to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin. Clin Cancer Res. 2006, 12: 2575-2582. 10.1158/1078-0432.CCR-05-2448.
Mortara L, Balza E, Sassi F, Castellani P, Carnemolla B, De Lerma Barbaro A, Fossati S, Tosi G, Accolla RS, Borsi L: Therapy-induced antitumor vaccination by targeting tumor necrosis factor-a to tumor vessels in combination with melphalan. Eur J Immunol. 2007, 37: 3381-3392. 10.1002/eji.200737450.
Balza E, Carnemolla B, Mortara L, Castellani P, Soncini D, Accolla RS, Borsi L: Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFalpha. Int J Cancer. 2010, 127: 101-110. 10.1002/ijc.25018.
Takeshima T, Chamoto K, Wakita D, Ohkuri T, Togashi Y, Shirato H, Kitamura H, Nishimura T: Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Res. 2010, 70: 2697-2706. 10.1158/0008-5472.CAN-09-2982.
Lee J, Moran JP, Fenton BM, Koch CJ, Frelinger JG, Keng PC, Lord EM: Alteration of tumour response to radiation by interleukin-2 gene transfer. Br J Cancer. 2000, 82: 937-944. 10.1054/bjoc.1999.1022.
Yamini B, Yu X, Pytel P, Galanopoulos N, Rawlani V, Veerapong J, Bickenbach K, Weichselbaum RR: Adenovirally delivered tumor necrosis factor-alpha improves the antiglioma efficacy of concomitant radiation and temozolomide therapy. Clin Cancer Res. 2007, 13: 6217-6223. 10.1158/1078-0432.CCR-07-1421.
Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM: Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 2005, 174: 7516-7523.
Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, Neijssen J: Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006, 203: 1259-1271. 10.1084/jem.20052494.
Liao YP, Wang CC, Butterfield LH, Economou JS, Ribas A, Meng WS, Iwamoto KS, McBride WH: Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells. J Immunol. 2004, 173: 2462-2469.
Zitvogel L, Kepp O, Kroemer G: Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol. 2011, 8: 151-160. 10.1038/nrclinonc.2010.223.